Literature DB >> 16807664

Arsenic carcinogenesis in the skin.

Hsin-Su Yu1, Wei-Ting Liao, Chee-Yin Chai.   

Abstract

Chronic arsenic poisoning is a world public health issue. Long-term exposure to inorganic arsenic (As) from drinking water has been documented to induce cancers in lung, urinary bladder, kidney, liver and skin in a dose-response relationship. Oxidative stress, chromosomal abnormality and altered growth factors are possible modes of action in arsenic carcinogenesis. Arsenic tends to accumulate in the skin. Skin hyperpigmentation and hyperkeratosis have long been known to be the hallmark signs of chronic As exposure. There are significant associations between these dermatological lesions and risk of skin cancer. The most common arsenic-induced skin cancers are Bowen's disease (carcinoma in situ), basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Arsenic-induced Bowen's disease (As-BD) is able to transform into invasive BCC and SCC. Individuals with As-BD are considered for more aggressive cancer screening in the lung and urinary bladder. As-BD provides an excellent model for studying the early stages of chemical carcinogenesis in human beings. Arsenic exposure is associated with G2/M cell cycle arrest and DNA aneuploidy in both cultured keratinocytes and As-BD lesions. These cellular abnormalities relate to the p53 dysfunction induced by arsenic. The characteristic clinical figures of arsenic-induced skin cancer are: (i) occurrence on sun-protected areas of the body; (ii) multiple and recrudescent lesions. Both As and UVB are able to induce skin cancer. Arsenic treatment enhances the cytotoxicity, mutagenicity and clastogenicity of UV in mammalian cells. Both As and UVB induce apoptosis in keratinocytes by caspase-9 and caspase-8 signaling, respectively. Combined UVB and As treatments resulted in the antiproliferative and proapoptotic effects by stimulating both caspase pathways in the keratinocytes. UVB irradiation inhibited mutant p53 and ki-67 expression, as well as increased in the number of apoptotic cells in As-BD lesions which resulted in an inhibitory effect on proliferation. As-UVB interaction provides a reasonable explanation for the rare occurrences of arsenical cancer in the sun-exposed skin. The multiple and recurrent skin lesions are associated with cellular immune dysfunction in chronic arsenism. A decrease in peripheral CD4+ cells was noticed in the inhabitants of arsenic exposure areas. There was a decrease in the number of Langerhans cells in As-BD lesion which results in an impaired immune function on the lesional sites. Since CD4+ cells are the target cell affected by As, the interaction between CD4+ cells and epidermal keratinocytes under As affection might be closely linked to the pathogenesis of multiple occurrence of arsenic-induced skin cancer. In this review, we provide and discuss the pathomechanisms of arsenic skin cancer and the relationship to its characteristic figures. Such information is critical for understanding the molecular mechanism for arsenic carcinogenesis in other internal organs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807664     DOI: 10.1007/s11373-006-9092-8

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  63 in total

Review 1.  State of the science review of the health effects of inorganic arsenic: Perspectives for future research.

Authors:  Paul B Tchounwou; Clement G Yedjou; Udensi K Udensi; Maricica Pacurari; Jacqueline J Stevens; Anita K Patlolla; Felicite Noubissi; Sanjay Kumar
Journal:  Environ Toxicol       Date:  2018-12-04       Impact factor: 4.119

2.  Aberrant cell proliferation by enhanced mitochondrial biogenesis via mtTFA in arsenical skin cancers.

Authors:  Chih-Hung Lee; Shi-Bei Wu; Chien-Hui Hong; Wei-Ting Liao; Ching-Ying Wu; Gwo-Shing Chen; Yau-Huei Wei; Hsin-Su Yu
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

3.  Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposure.

Authors:  Xu-Jun Qin; Wenlan Liu; Ying-Na Li; Xi Sun; Chun-Xu Hai; Laurie G Hudson; Ke Jian Liu
Journal:  Toxicol Sci       Date:  2012-03-02       Impact factor: 4.849

4.  A possible new mechanism and drug intervention for kidney damage due to arsenic poisoning in rats.

Authors:  Yu-Yan Xu; Qi-Bing Zeng; Mao-Lin Yao; Chun Yu; Jun Li; Ai-Hua Zhang
Journal:  Toxicol Res (Camb)       Date:  2016-01-05       Impact factor: 3.524

5.  Kinetics and thermodynamics of zinc(II) and arsenic(III) binding to XPA and PARP-1 zinc finger peptides.

Authors:  Juliana Huestis; Xixi Zhou; Li Chen; Changjian Feng; Laurie G Hudson; Ke Jian Liu
Journal:  J Inorg Biochem       Date:  2016-08-02       Impact factor: 4.155

6.  Proteomic analysis of low dose arsenic and ionizing radiation exposure on keratinocytes.

Authors:  Susanne R Berglund; Alison R Santana; Dan Li; Robert H Rice; David M Rocke; Zelanna Goldberg
Journal:  Proteomics       Date:  2009-04       Impact factor: 3.984

7.  Reduction of arsenite-enhanced ultraviolet radiation-induced DNA damage by supplemental zinc.

Authors:  Karen L Cooper; Brenee S King; Monica M Sandoval; Ke Jian Liu; Laurie G Hudson
Journal:  Toxicol Appl Pharmacol       Date:  2013-03-21       Impact factor: 4.219

8.  Candidate single nucleotide polymorphism markers for arsenic responsiveness of protein targets.

Authors:  Raphael D Isokpehi; Hari H P Cohly; Matthew N Anyanwu; Rajendram V Rajnarayanan; Paul B Tchounwou; Udensi K Udensi; Barbara E Graham-Evans
Journal:  Bioinform Biol Insights       Date:  2010-10-11

9.  Intakes of several nutrients are associated with incidence of arsenic-related keratotic skin lesions in Bangladesh.

Authors:  Stephanie Melkonian; Maria Argos; Yu Chen; Faruque Parvez; Brandon Pierce; Alauddin Ahmed; Tariqul Islam; Habibul Ahsan
Journal:  J Nutr       Date:  2012-10-17       Impact factor: 4.798

10.  Impact of smoking and chewing tobacco on arsenic-induced skin lesions.

Authors:  Anna-Lena Lindberg; Nazmul Sohel; Mahfuzar Rahman; Lars Ake Persson; Marie Vahter
Journal:  Environ Health Perspect       Date:  2009-11-03       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.